We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Intellia已提交全球首个体内CRISPR疗法lonvo-z用于遗传性血管性水肿（HAE）的申请。发作减少87%，62%无发作。风险、市场和预测分析。阅读。
